<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Схожие документы

• <i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
  по: Zachary D. Epstein-Peterson, и др.
  Опубликовано: (2024-08-01)
• Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
  по: Richard J. Lin, и др.
  Опубликовано: (2021-07-01)
• Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
  по: Giulio Cassanello, и др.
  Опубликовано: (2024-09-01)
• Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma
  по: Anita Kumar, и др.
  Опубликовано: (2019-04-01)
• T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
  по: Alison J. Moskowitz, и др.
  Опубликовано: (2022-10-01)